ATM and cancer: In addition to the BRCA1/2m—PARPis couple, increasing evidence demonstrates that synthetic lethality may also take place following ATR inhibition in HDR-deficient tumors carrying inactivated ATM [265,266,267], with active ongoing phase II clinical trials testing two such agents: berzosertib (NCT02567409, NCT03517969 and NCT02595892) and ceralasertib (NCT03330847, NCT03328273, NCT03787680 and NCT02937818), in a variety of human cancers.